SuperworthKrystal Biotech market cap KRYS
Share price times shares outstanding: what the whole company sells for, since 2017.
- Today, Oct 23, 2026
- $9.2B
- Highest close in our data
- $11.1B
- Jul 2026
Krystal Biotech is worth $9.2B at the close on Oct 23, 2026, at $311.50 a share.
That is up 71% over the last year and up 729% over five years.
Its highest close in our data was $11.1B in Jul 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $9.2B | $7.2B | $11.1B | +26% |
| 2025 | $7.3B | $3.6B | $7.3B | +60% |
| 2024 | $4.6B | $3.1B | $6.1B | +31% |
| 2023 | $3.5B | $1.9B | $3.5B | +72% |
| 2022 | $2B | $1.2B | $2.1B | +31% |
| 2021 | $1.6B | $885.3M | $1.8B | +32% |
| 2020 | $1.2B | $642.8M | $1.2B | +14% |
| 2019 | $1B | $304.5M | $1.1B | +249% |
| 2018 | $298.5M | $88.2M | $366.2M | +177% |
| 2017 | $107.7M | $92.3M | $107.7M | n/a |
Against its peers
Companies in Biotechnology nearest Krystal Biotech's size, closest first, today.
| Company | Market cap |
|---|---|
| KRYSKrystal Biotech | $9.2B |
| RGENRepligen | $10B |
| TECHBIO-TECHNE | $11.4B |
| HALOHalozyme Therapeutics | $14.3B |
| NBIXNeurocrine Biosciences | $14.5B |
| EXELExelixis | $16B |
| INCYIncyte | $23.5B |
| UTHRUnited Therapeutics | $25.2B |
| ALNYAlnylam Pharmaceuticals | $30B |
| ADMAAdma Biologics | $2.4B |
| VCELVericel | $2.2B |
| Peer median | $14.4B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Krystal Biotech
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.